Drug Profile
GC 007F
Alternative Names: Anti CD19 chimeric antigen receptor T cell therapy - Gracell Biotechnology; Anti CD19 U-CAR-T cell therapy; CD19-F-CAR-T; FasT CAR-19; GC007F; GC007F CAR-T cell immunotherapyLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Gracell Biotechnology
- Developer Gracell Biotechnology; Shanghai Tongren Hospital
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 22 Feb 2024 Gracell Biotechnology has been acquired by AstraZeneca
- 28 Feb 2022 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, Refractory metastatic disease, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 28 May 2021 No recent reports of development identified for phase-I development in B-cell lymphoma(Recurrent, Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)